In the iconic "Sound of Music" score, "My Favorite Things," a young Julie Andrews lists snowflakes as objects that bring her ...

From certain variations of the Honda Civic Type R to some of Toyota's most potent offerings, many have never made it to ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Investors didn't seem to be in a forgiving mood with the company's quarterly and annual guidance. That morning, Vertex revealed that its total revenue was slightly over $192 million in the third ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Vertex Pharmaceuticals plans by year-end to submit part of a license application to regulators for its kidney-disease treatment, and to have the full application submitted by first half of next year.

Your browser does not support the audio element. Vertex AI Workbench is a managed Jupyter environment in Google Cloud. It ships with native integration with BigQuery ...

V2X (NYSE:VVX) announced the sale of 2 million shares of its common stock by Vertex Aerospace Holdco. The company is not selling any shares in this offering and will not receive any proceeds. The ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S.

There are gentle migration strategies that can delay the move away from Windows 10, which Microsoft will stop supporting in October 2025. Technically (and maybe even psychologically), the easiest step ...